F-18 AV 1451
Phase 1Small molecule
F-18 AV 1451 is one of 51 small molecule programs targeting Frontotemporal Dementia. It is currently in Phase 1.
2
Indications
4
Total Trials
3
Active Trials
50
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
38 competitors in Frontotemporal Dementia
#DrugCompanyPhaseTrials
1Namenda
AbbVieApproved
Celexa
AbbVieApproved
Gocovri
GGrupo Espanol de Tumores Neuroendocrinos
Approved
Rayos
RRoxane Laboratories
Approved
Rapamune
PPrism Pharmaceuticals
Approved
Glucophage
EMD SeronoApproved
Namenda
FForest Laboratories
Phase 3
Brintellix
TakedaPhase 2
Tasmar
BBausch Health Americas, Inc.
Phase 2
Cesamet
BBausch Health Americas, Inc.
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Frontotemporal Dementia1 trial
Alzheimer's Disease1 trial
Progressive Supranuclear Palsy1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for F-18 AV 1451. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- MMayo Clinic